| Autor: |
Duhig, KE, Seed, PT, Myers, JE, Bahl, R, Bambridge, G, Barnfield, S, Ficquet, J, Girling, JC, Khalil, A, Shennan, AH, Chappell, LC, Hunter, RM, Duhig, K E, Seed, P T, Myers, J E, Girling, J C, Shennan, A H, Chappell, L C, Hunter, R M |
| Předmět: |
|
| Zdroj: |
BJOG: An International Journal of Obstetrics & Gynaecology; Oct2019, Vol. 126 Issue 11, p1390-1398, 9p, 1 Diagram, 3 Charts |
| Abstrakt: |
Objective: To calculate the cost-effectiveness of implementing PlGF testing alongside a clinical management algorithm in maternity services in the UK, compared with current standard care.Design: Cost-effectiveness analysis.Setting: Eleven maternity units participating in the PARROT stepped-wedge cluster-randomised controlled trial.Population: Women presenting with suspected pre-eclampsia between 20+0 and 36+6 weeks' gestation.Methods: Monte Carlo simulation utilising resource use data and maternal adverse outcomes.Main Outcome Measures: Cost per maternal adverse outcome prevented.Results: Clinical care with PlGF testing costs less than current standard practice and resulted in fewer maternal adverse outcomes. There is a total cost-saving of UK£149 per patient tested, when including the cost of the test. This represents a potential cost-saving of UK£2,891,196 each year across the NHS in England.Conclusions: Clinical care with PlGF testing is associated with the potential for cost-savings per participant tested when compared with current practice via a reduction in outpatient attendances, and improves maternal outcomes. This economic analysis supports a role for implementation of PlGF testing in antenatal services for the assessment of women with suspected pre-eclampsia.Tweetable Abstract: Placental growth factor testing for suspected pre-eclampsia is cost-saving and improves maternal outcomes. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text